^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TQB3909
i
Other names: TQB3909
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sino Biopharm
Drug class:
Bcl2 inhibitor
Related drugs:
7ms
A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) (clinicaltrials.gov)
P1/2, N=93, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Feb 2024 --> May 2024
Enrollment open • Trial initiation date
|
TQB3909 • rovadicitinib (TQ05105)
11ms
A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) (clinicaltrials.gov)
P1/2, N=93, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1/2 trial
|
TQB3909 • rovadicitinib (TQ05105)
11ms
A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy (clinicaltrials.gov)
P1, N=208, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1 trial
|
TQB3909
1year
A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets (clinicaltrials.gov)
P1, N=40, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1 trial
|
itraconazole • TQB3909 • rifampicin
1year
TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (clinicaltrials.gov)
P1/2, N=39, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
New P1/2 trial
|
BCL2 (B-cell CLL/lymphoma 2)
|
TQB3909
1year
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . (clinicaltrials.gov)
P1/2, N=107, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
PLCG2 (Phospholipase C Gamma 2)
|
TQB3909
over1year
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . (clinicaltrials.gov)
P1/2, N=107, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1/2 trial
|
PLCG2 (Phospholipase C Gamma 2)
|
TQB3909
almost2years
A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer (clinicaltrials.gov)
P1/2, N=65, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1/2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
TQB3909
almost3years
A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors (clinicaltrials.gov)
P1, N=126, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Nov 2021 --> Feb 2022
Enrollment open • Trial initiation date • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
|
TQB3909
3years
A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors (clinicaltrials.gov)
P1, N=126, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Initiation date: Aug 2021 --> Nov 2021
Clinical • Trial initiation date • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
|
TQB3909
Share via
